Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines
Microtubules are currently ranked one of the most validated targets for chemotherapy; with clinical use of microtubule targeting agents (MTAs) extending beyond half a century. Recent research has focused on the development of novel MTAs to combat drug resistance and drug associated toxicities. Of particular interest are compounds structurally different to those currently used within the clinic. The pyrrolo-1, 5-benzoxazepines (PBOXs) are a structurally distinct novel group of anti-cancer agents, some of which target tubulin. Herein, we review the chemistry, mechanism of action, preclinical development of the PBOXs and comparisons with clinically relevant chemotherapeutics. The PBOXs induce a range of cellular responses including; cell cycle arrest, apoptosis, autophagy, anti-vascular and anti-angiogenic effects. The apoptotic potential of the PBOXs extends across a wide spectrum of cancer-derived cell lines, by targeting tubulin and multiple molecular pathways frequently deregulated in human cancers. Extensive experimental data suggest that combining the PBOXs with established chemotherapeutics or radiation is therapeutically advantageous. Pre-clinical highlights of the PBOXs include; cancer specificity and improved therapeutic efficacy as compared to some current first line therapeutics.
Conclusion We found a high economic impact of health care systems treating ICC in a poor region of Brazil. These estimates could be applicable to further evaluations of the cost-effectiveness of preventing and treating ICC.Resumo Objetivo O objetivo principal do presente estudo foi estimar os custos anuais por paciente do tratamento do c âncer do colo do útero (CCU) invasivo em um centro de oncologia no Brasil, sob a perspectiva da sociedade, considerando os custos diretos médicos, diretos não médicos e indiretos. Métodos Foi realizado um estudo descritivo de análise de custo...
CONCLUSIONS Anorectal GIST is a rare tumor that has a better outcome compared with GISTs arising at other sites in the gastrointestinal tract. PMID: 31326976 [PubMed - in process]
How do you respond when patients with a good prognosis want to delay chemotherapy to try an anticancer diet for a few months or visit an unregulated clinic for unproven therapies? I’m asking because of an alarming finding of ASCO’s 2018 National Cancer Opinion Survey: “Nearly 4 in 10 Americans believe cancer can be cured solely […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
(American College of Surgeons) Women with breast cancer should start postoperative chemotherapy, when recommended, ideally within four months of their cancer diagnosis because new study findings show that waiting longer is associated with poorer overall survival.
young female, known to have a metastatic breast cancer, since 5 years. In 2017, she developed secondary lesions in the brain with positive CSF. She receives 30Gy/10 fr whole brain radiation, with intra-thecal chemotherapy. A month ago, she developed gait disturbances with blurred speech an hemifacial paresia. Brain MRI showed a solitary secondary lesion, 1.5 cm involving the left middle cerebral peduncle with extensive edema. No signs of meningeal disease. Pet CT : NED outside the brain... SRS for BS lesion: what dose?
ConclusionEarly tumor shrinkage and DpR might be predictive markers only in left-sided CRCs with liver metastasis. Each imaging analysis has a different value based on the primary and metastatic sites.
Nature Reviews Clinical Oncology, Published online: 22 July 2019; doi:10.1038/s41571-019-0257-6An urgent clinical need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches include the targeting of metastatic pancreatic cancer that harbours germline BRCA mutations with poly(ADP-ribose) polymerase inhibitors as maintenance therapy following platinum-based chemotherapy.
ConclusionsThese data support further investigation of A1mcMMAF in combination with platinum-based chemotherapy in ovarian and other cancer treatments.
ConclusionPatients withKRAS-mutant lung adenocarcinoma have a poorer outcome on pemetrexed-based first-line chemotherapy. WhetherKRAS-mutant NSCLCs should be excluded from pemetrexed-containing regimens should be assessed prospectively.
ConclusionsIn early-stage LCNEC, adjuvant chemotherapy appears to confer an additional overall survival advantage only in patients with completely resected stage IB LCNEC and not for patients with completely resected stage IA LCNEC.